CYP2D6 and tamoxifen: DNA matters in breast cancer.
摘要：
Tamoxifen is the most widely used anti-oestrogen for the treatment of hormone-dependent breast cancer. The pharmacological activity of tamoxifen is dependent on its conversion by the hepatic drug-metabolizing enzyme cytochrome P450 2D6 (CYP2D6) to its abundant metabolite, endoxifen. Patients with reduced CYP2D6 activity, as a result of either their genotype or induction by the co-administration of drugs that inhibit CYP2D6 function, produce little endoxifen and seem to derive inferior therapeutic benefit from tamoxifen. Here we review the existing data that relate CYP2D6 genotypes to response to tamoxifen and discuss whether the analysis of the CYP2D6 genotype might be an early example of a pharmacogenetic tool for optimizing breast cancer therapy.
展开
DOI：
10.1038/nrc2683
被引量：
年份：
2009
Nature
(全网免费下载)
Nature
Springer
国家科技图书文献中心
(权威机构)
Wiley
查看更多
Semantic Scholar
掌桥科研
万方医学
dx.doi.org
NCBI
Europe PMC
NCBI
ResearchGate
ProQuest
EBSCO
EBSCO
EBSCO
onAcademic
ftp.palgrave-journals.com
学术范
bvsalud.org
en.zl50.com
erc.endocrinology-journals.org
mendeley.com
pubfacts.com
scienceopen.com
readcube.com
www.socolar.com
学术范
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
引用走势
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
